Cargando…

MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer

Immune checkpoint inhibitors (ICIs) therapy elicits admirable anti-tumor responses across many types of cancer. Growing evidence point to a link to Mediator complex subunit 12 (MED12) and DNA damage repair (DDR) and TGF-β signing, while the clinical data on the association of MED12 and ICIs response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yong, Tan, Yuan, Zhang, Qin, Duan, Qianqian, Chen, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618186/ https://www.ncbi.nlm.nih.gov/pubmed/36309740 http://dx.doi.org/10.1186/s40001-022-00856-z

Ejemplares similares

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

How to use immune checkpoint inhibitor in ovarian cancer?
por: Park, Junsik, et al.
Publicado: (2019)

Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2022)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’
por: Takada, K., et al.
Publicado: (2022)

Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
por: Suzuki, Rika, et al.
Publicado: (2023)

Comment on ‘Toxicities associated with immune checkpoint inhibitors: A systematic study’
por: Hosseini, Mohammad-Salar, et al.
Publicado: (2023)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy
por: Zhu, Yan, et al.
Publicado: (2022)

Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Takimoto, Takayuki
Publicado: (2020)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Reply to Takimoto: Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Yamasaki, Masahiro, et al.
Publicado: (2020)

Immune-related genetic prognostic index to predict prognosis and immune checkpoint inhibitor therapy efficiency in acute myeloid leukemia
por: Cao, Xunhong, et al.
Publicado: (2023)

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature
por: Kang, Yan, et al.
Publicado: (2023)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect
por: Han, Xiaying, et al.
Publicado: (2022)

GenBank and PubMed: How connected are they?
por: Miller, Holly, et al.
Publicado: (2009)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2022)

Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment
por: Wang, Aoyun, et al.
Publicado: (2022)

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
por: Matsuo, Norikazu, et al.
Publicado: (2019)

Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database
por: HUANG, Sifu, et al.
Publicado: (2021)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning
por: Polano, Maurizio, et al.
Publicado: (2019)

IL-34 and Immune Checkpoint Inhibitors Resistant through Macrophages: Pan-Cancer Overview
por: Safi, Mohammed, et al.
Publicado: (2023)

TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
por: Qiu, Tianzhu, et al.
Publicado: (2022)

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
por: Zhang, Zhen, et al.
Publicado: (2021)

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
por: Long, Junyu, et al.
Publicado: (2021)

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals
por: Shapiro, Daniel D., et al.
Publicado: (2023)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

The Pan-American Medical Congress
Publicado: (1891)

Frequent MED12 mutations in phyllodes tumours of the breast
por: Yoshida, M, et al.
Publicado: (2015)

Drug‐Induced Liver Injury by Checkpoint Inhibitors: Benefit of a Causality Assessment Tool
por: Weber, Sabine, et al.
Publicado: (2020)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_277mr44aab82tan4u9rkelr7kq